Microbial therapeutics: New opportunities for drug delivery

Author(s)
Jimenez, Miguel; Langer, Robert S; Traverso, Carlo Giovanni
Thumbnail
DownloadPublished version (703.5Kb)
Terms of use
Creative Commons Attribution-Noncommercial-Share Alike http://creativecommons.org/licenses/by-nc-sa/4.0/
Metadata
Show full item record
Abstract
With >40 clinical trials underway, we are nearing the first FDA-approved live microbial therapeutic. Here, Giovanni Traverso, MIT and Harvard Medical School Assistant Professor, and colleagues Miguel Jimenez and Institute Professor Robert Langer from MIT discuss the significant challenges of administering live microorganisms to patients and the opportunities for drug delivery of these new complex therapeutics.
Date issued
2019-04
URI
https://hdl.handle.net/1721.1/126020
Department
David H. Koch Institute for Integrative Cancer Research at MIT; Massachusetts Institute of Technology. Department of Biological Engineering; Massachusetts Institute of Technology. Department of Chemical Engineering; Massachusetts Institute of Technology. Department of Mechanical Engineering
Journal
Journal of Experimental Medicine
Publisher
Rockefeller University Press
Citation
Jimenez, Miguel et al. "Microbial therapeutics: New opportunities for drug delivery." Journal of Experimental Medicine 216, 5 (April 2019): 1005–1009 © 2019 MIT
Version: Final published version
ISSN
0022-1007
1540-9538
Collections